BEDFORD, Mass., April 19, 2016 /PRNewswire/ -- Integral BioSystems LLC, Boston area CRO specializing in ophthalmological pharmaceutical formulation development, will be in the spotlight as a participating exhibitor during the ARVO 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology from May 1-May 4, 2016, to be held at the Seattle State Convention Center.
With almost 23 years of experience in all phases of cell and tissue targeted, sustained release pharmaceutical formulation development, the firm's CEO and President, Dr. Shikha P. Barman, will be on hand to discuss the specific requirements of interested attendees. In addition, Integral BioSystems will be presenting two posters.
About the Symposium
The ARVO 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology will cover subjects like Medicine, Eyesight, Vision, Ophthalmology, and Eye Health. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. It is anticipated that nearly 11,000 people will participate in this Meeting.
About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.
The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes. www.integralbiosystems.com
Dave Karasic, Esq.
Chief Operations Officer
Integral BioSystems LLC
SOURCE Integral BioSystems LLC